Recent Antibiotics Hailed as a 'Turning Point' in Treating Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.
A Global Health Concern
Gonorrhoea infections are on the rise globally, with estimates suggesting over 82 million infections each year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.
“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the very limited available drugs currently available.”
Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.
Recent Therapies Gain Approval
Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that focused deployment of this new drug will help hinder the development of resistance.
Gepotidacin, originating from the pharmaceutical company GSK, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.
A Unique Partnership
This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to see it through.
“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”
Research Study Data and Worldwide Availability
Based on results published in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The trial involved over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.
As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.
Medical professionals directly involved have shared hope. Having a one-pill regimen of this kind is seen as a "critical tool" for managing the epidemic. This is considered vital to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.
